Phosphorylated heterodimers of ERBB2 ECD mutants and EGFR, in complex with GRB2:GAB1, bind PI3K

Stable Identifier
R-HSA-9665415
Type
Reaction [binding]
Species
Homo sapiens
Compartment
cytosol, plasma membrane
ReviewStatus
5/5
Locations in the PathwayBrowser
Expand all
General
SVG | 
PNG
Low
Medium
High
 | PPTX  | SBGN
Phosphorylated heterodimers of ERBB2 ECD mutants and EGFR, in complex with GRB2:GAB1, bind PI3K
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout
ERBB2 G309E and ERBB2 S310F activate PI3K/AKT signaling, demonstrated by activating phosphorylation of AKT1 (Greulich et al. 2012). It is assumed that phosphorylated heterodimers of ERBB2 ECD mutants and EGFR, like the wild type heterodimers of ERBB2 and EGFR, can bind to the GRB2:GAB1 complex, leading to the recruitment of the PI3K complex.
Literature References
PubMed ID Title Journal Year
22908275 Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2

Walker, SR, Greulich, H, Pho, NH, Banerji, S, Berger, AH, Lawrence, MS, Getz, G, Frank, D, Tanaka, KE, Chen, TH, Mani, DR, Liao, R, Imielinski, M, Winckler, W, Lee, SH, Meyerson, M, Hahn, WC, Wong, KK, Ambrogio, L, Kaplan, B, Cho, J, Mertins, P, Carr, SA, Jaffe, JD, Zhang, X, Eck, MJ, Yun, CH, Zhang, J

Proc. Natl. Acad. Sci. U.S.A. 2012
Participants
Input
Output
Participates
as an event of
Normal reaction
Binding of PI3K to GRB2:GAB1 in complex with phosphorylated heterodimer of ERBB2 and EGFR (Homo sapiens)
Functional status

Gain of function of p-6Y-ERBB2 ECD mutants:EGF:p-6Y-EGFR:GRB2:GAB1 [plasma membrane]

Normal Entity
Disease Entity
Status
Disease
Name Identifier Synonyms
cancer DOID:162 malignant tumor, malignant neoplasm, primary cancer
Authored
Orlic-Milacic, M  (2019-10-30)
Reviewed
Bose, R  (2019-10-25)
Kancha, RK  (2019-11-03)
Krishna, A  (2019-10-25)
Created
Orlic-Milacic, M  (2019-10-30)
Cite Us!